BHARAT BIOTECH’S COVAXIN PHASE 3 INTERIM EFFICACY AT 81%
Bharat Biotech recently announced the Phase 3 clinical trial results for its coronavirus vaccine candidate, Covaxin. “Covaxin demonstrated 81 percent interim efficacy in preventing COVID-19 in those without prior infection after the second dose,” the […]